COMMUNIQUÉS West-GlobeNewswire

Vireo Growth Inc. Engages Independent Trading Group (ITG), Inc. as Market Maker
06/07/2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (CSE: VREO) (OTCQX: VREOF) (“Vireo” or the “Company”), today announced that it has engaged the services of Independent Trading Group ("ITG") to provide [...]
Elicio Therapeutics Announces Closing of $15 Million Registered Direct Offering
06/07/2026
BOSTON, July 06, 2026 (GLOBE NEWSWIRE) -- Elicio Therapeutics, Inc. (Nasdaq: ELTX) (“Elicio” or the “Company”) , a clinical-stage biotechnology company developing next-generation immunotherapies for KRAS-driven cancers [...]
Organogenesis Announces FDA Acceptance of Biologics License Application for ReNu® for the Management of Symptomatic Knee Osteoarthritis
06/07/2026
PDUFA Target Action Date Set for April 24, 2027 CANTON, Mass., July 06, 2026 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on product solutions for the [...]
Cosmos Health Share Buyback Increases to 3.64 Million Shares; Continues Open Market Purchases
06/07/2026
CHICAGO, July 06, 2026 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM) , a diversified, vertically integrated global healthcare group, today announced that it has repurchased an [...]
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
06/07/2026
Media Release COPENHAGEN, Denmark; July 6, 2026 TEPKINLY ® (epcoritamab) plus lenalidomide and rituximab (R 2 ) is the first and only bispecific-based therapy approved in Europe for the treatment of follicular lymphoma [...]
Alberta Cancer Foundation invests $35-million to power cancer clinical trials for Albertans
06/07/2026
Historic funding over the next five years strengthens Alberta’s newly launched 10-Year Cancer Care Strategy CALGARY, Alberta, July 06, 2026 (GLOBE NEWSWIRE) -- The Alberta Cancer Foundation is investing $35-million to [...]
Clareo Plastic Surgery Named Best Plastic Surgery Practice in Boston
06/07/2026
Cliche Magazine Recognizes Clareo for Excellence in Cosmetic Procedures Chestnut Hill, MA, July 06, 2026 (GLOBE NEWSWIRE) -- Clareo Plastic Surgery has been honored as the best plastic surgery practice in Boston, [...]
FOXO TECHNOLOGIES INC. CEO SEAMUS LAGAN PROVIDES MID-YEAR UPDATE TO SHAREHOLDERS
06/07/2026
WEST PALM BEACH, FL, July 06, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXOD/FOXO) (the “Company”) announces the following mid-year update to shareholders by the Company’s Chief Executive Officer Seamus [...]
IPSEN - Buy-back programme - Art 5 of MAR - Week 27- 2026
06/07/2026
Aggregated presentation by day and by market Weekly report on share repurchases from 30th June to 03rd July 2026 Name of the Issuer Identify code of the Issuer Transaction day Identify code of the financial instrument [...]
Zealand Pharma - Transactions related to share buy-back program (week 27, 2026)
06/07/2026
Company announcement No. 31 / 2026 Zealand Pharma - Transactions related to share buy-back program (week 27, 2026) Copenhagen, Denmark, July 6, 2026 – Zealand Pharma A/S ("the Company" or “Zealand Pharma”) (Nasdaq: ZEAL [...]
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 27 - 2026
06/07/2026
Présentation agrégée par jour et par marché Déclaration des transactions sur actions propres réalisées du 30 juin au 3 juillet 2026 Nom de l'émetteur Code identifiant de l'émetteur (code LEI) Jour de la transaction Code [...]
Scilex Holding Company Announces Dream Bowl I Meme Coin Tokens Commence Trading on the Biconomy Exchange on July 6, 2026
06/07/2026
PALO ALTO, Calif., July 06, 2026 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex” or the “Company”) (Nasdaq: SCLX), an innovative revenue-generating company focused on acquiring, developing, and commercializing non- [...]
MESA LABS DECLARES QUARTERLY DIVIDEND
06/07/2026
Lakewood, Colo., July 06, 2026 (GLOBE NEWSWIRE) -- Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0 [...]
NewGen’s Advanced Cytometry Platform Poised for Major UAE/GCC Expansion with Big Four Valuation of US$19 Million
06/07/2026
Midpoint equity value for planned UAE cell sorting entity highlights significant growth runway in high-infertility, medical-tourism hotspot Senior Strategic Advisor Nadeem Malik, former CEO of Genetics and IVF Institute [...]
Correction: Inspire Medical Systems, Inc. to Report Second Quarter 2026 Financial Results on August 3, 2026
06/07/2026
MINNEAPOLIS, July 06, 2026 (GLOBE NEWSWIRE) -- This press release corrects the earnings release date included in the earlier version issued on July 6, 2026. No other information has changed. Inspire Medical Systems, Inc [...]
Vivos Inc. (OTCQB: RDGL) Receives U.S. FDA Approval for Investigational Device Exemption (IDE) to Initiate Human Clinical Feasibility Study for RadioGel® Precision Radionuclide Therapy™
06/07/2026
Kennewick, WA, July 06, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), a medical device company pioneering Precision Radionuclide Therapy ™ (PRnT) for the treatment of cancerous tumors, is pleased to announce that [...]
LENZ Therapeutics Announces Launch of New Telehealth Prescribing Option to Accelerate Patient Access to VIZZ® for the Treatment of Presbyopia
06/07/2026
VIZZ is now available for those who qualify through a convenient telehealth platform in addition to existing access through eye care professionals Telehealth offers patients the convenience of an integrated online [...]
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor Symposium
06/07/2026
SAN DIEGO, July 06, 2026 (GLOBE NEWSWIRE) -- Belite Bio , Inc (NASDAQ: BLTE) (“Belite Bio®” or the “Company”), a clinical-stage drug development company focused on advancing novel therapeutics targeting degenerative [...]
PharmAla Completes GMP Manufacturing of Drug Substance components for ALA-002 Provides Corporate Update Regarding ALA-002 Asset
06/07/2026
TORONTO, July 06, 2026 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (CSE: MDMA)(OTCQB: MDXXF) , a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives [...]

Pages